Navigation Links
Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease

the Total Maximal Chorea Score were statistically significantly reduced, as compared to baseline in the open-label study, within subjects with significant benefits seen throughout the study's duration. The most commonly observed adverse events were sleepiness, depressed mood, anxiety, chorea, insomnia, and an inner feeling of restlessness (akathisia). Serious adverse events judged by study investigators to be possibly or probably related to tetrabenazine use included: fall (two patients), pneumonia (two patients), increased depression, akathisia, agitation and trouble swallowing (dysphagia). Nine patients withdrew from the study due to adverse events.

About Huntington's Disease

Huntington's disease (HD) is an inherited degenerative brain disorder that affects 1 in 10,000 Americans and causes involuntary movements (chorea) and deterioration in the ability to think, walk, talk and reason. HD is hereditary, with each child of an affected parent having a 50% chance of inheriting the gene that causes HD. The disease does not skip generations, and everyone who carries the gene will develop the disease. Most people with HD develop the illness between the ages of 30 and 45. At this time, there is no way to stop, slow or reverse the course of HD, and current treatments are aimed at alleviating the troublesome symptoms of the disease.

About the Huntington Study Group

This clinical study was organized and conducted by the Huntington Study Group, a non-profit, cooperative group of Huntington's disease experts from medical centers in North America, Europe and Australia who are dedicated to improving treatment for persons affected by Huntington's disease. For more information, visit their web sites at www.Huntington-Study-Group.org and www.HuntingtonProject.org.

About Tetrabenazine

Tetrabenazine has been licensed to Prestwick Pharmaceuticals, Inc. for marketing in the United States and Canada by Cambridge Laboratories (Ireland) Limited,
'"/>




Page: 1 2 3

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:3/2/2015)... 2015   , Boston Scientific to ... consideration of up to $1.65 billion, with $1.6 billion in ... alternatives for AMS, Women,s Health business , ... business Endo International plc (NASDAQ: ... into a definitive agreement with Boston Scientific (NYSE: ...
(Date:3/2/2015)...  BioMed Realty Trust, Inc. (NYSE: BMR ... feet of space in the most dynamic and valuable ... the termination of Vertex Pharmaceuticals, leases on three properties ... 28, 2015. BioMed Realty will receive a $14 million ... reposition the properties to meet the growing demand for ...
(Date:3/1/2015)... , March 1, 2015  An innovative interventional ... migraine sufferers sustained relief of their headaches, according ... of Interventional Radiology ,s Annual Scientific Meeting ... State University New York Empire State College in ... sphenopalatine ganglion (SPG) blocks to give patients enough ...
Breaking Medicine Technology:Endo Announces Divestiture of American Medical Systems' Men's and Prostate Health Businesses to Boston Scientific 2Endo Announces Divestiture of American Medical Systems' Men's and Prostate Health Businesses to Boston Scientific 3BioMed Realty Gets Back 313,000 Square Feet Of Valuable Real Estate In Cambridge Innovation District 2BioMed Realty Gets Back 313,000 Square Feet Of Valuable Real Estate In Cambridge Innovation District 3Image-guided treatment shown to break the migraine cycle 2Image-guided treatment shown to break the migraine cycle 3Image-guided treatment shown to break the migraine cycle 4
... of Proprietary siRNA Molecule in Acute ... ... Inc., a,development-stage pharmaceutical company focused on discovering and,developing novel RNA interference-based ... its proprietary product,candidate, AKIi-5, a siRNA compound discovered and developed by ...
... 16 AstraZeneca (NYSE:,AZN) today announced that the ... SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release,Tablets for maintenance treatment ... the FDA approved SEROQUEL XR for the acute ... experience high rates of symptom relapse, and as,a ...
Cached Medicine Technology:Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 2Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 3Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 4SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 2SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 3SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 4SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 5SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 6SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 7SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 8
(Date:3/1/2015)... To help healthcare organizations ... practices compliantly and profitably, MDreferralPRO and Vericle ... The interoperability between a strategic referral management ... management system is necessary for a healthcare ... referral management and development solution relies on ...
(Date:3/1/2015)... Orion, Metamora, Michigan (PRWEB) March 01, 2015 ... is approved to treat Overactive Bladder (OAB) symptoms, such as ... in adults when another type of medication (anticholinergic) does not ... a different treatment option that takes another approach to targeting ... , BOTOX® works on the nerves and bladder muscle, blocking ...
(Date:3/1/2015)... 01, 2015 A federal court ... ) scheduled to go to trial in October ... witness to provide testimony regarding the role an ... the Profemur device, Bernstein Liebhard LLP comments. According ... Northern District of Iowa on February 25th, Wright ...
(Date:3/1/2015)... GA (PRWEB) March 01, 2015 ... Evelyn King and Carolyn Roddy to the professional staff ... of Compliance, graduated from The Ohio State University-Mortiz College ... 15 years of experience working with several Fortune 500 ... in the area of corporate benefits. Her experiences range ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The MCA ... across Malaysia into one platform and gears towards the ... , A series of group talks in smaller groups ... Nation Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, Social ... raise awareness of Malaysian youths. , Young ...
Breaking Medicine News(10 mins):Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 2Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 3Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 4Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4
... Programming Kit and Software ,Separately From its Hearing Aids For the ... ... 2008 -- America Hears, Inc. , the leading online supplier ... of its hearing-aid programming software, Virtual Office, and announced it will ...
... and Cubicin is Driven Strongly by Agents, ... Report from AMR and Decision,Resources, MALVERN, ... Resources (AMR) and Decision Resources find that ... by methicillin-resistant Staphylococcus,aureus (MRSA), an overwhelming majority ...
... health threat, especially in underdeveloped areas , , TUESDAY, ... but neglected threat to global public health, new research ... PLoS Medicine , estimates that at least 421,000 ... suggesting the numbers could be as much as four ...
... Will Be Featured at ASN, EL SEGUNDO, ... of kidney care services for those diagnosed with ... Research(R) (DCR),recently contributed fifteen abstracts to the 41st ... of Nephrology. These,abstracts were developed both internally and ...
... media outlets ran stories about Dr. Sanford Siegal,s, ... October 30th, MIAMI, Nov. 4 Last ... ran stories on renowned physician, author,and weight loss ... Dr.,Siegal,s COOKIE DIET(R) weight loss system and hunger-controlling ...
... (TSX: RBM, OTCBB: RPBIF) today announced that S. Wayne ... Renshaw 10th Annual,Healthcare Conference on Tuesday, November 11 at ... in New York City., A Web cast of ... the event and will be,archived and available on a ...
Cached Medicine News:Health News:America Hears Introduces New and Improved Hearing-Aid Programming Software 2Health News:America Hears Introduces New and Improved Hearing-Aid Programming Software 3Health News:Activity Against MRSA is the Most Important Attribute Influencing Physicians' Antibiotic Selection for the Treatment of Skin and Skin Structure Infections 2Health News:Activity Against MRSA is the Most Important Attribute Influencing Physicians' Antibiotic Selection for the Treatment of Skin and Skin Structure Infections 3Health News:DaVita Abstracts Accepted into American Society of Nephrology Meeting 2Health News:DaVita Abstracts Accepted into American Society of Nephrology Meeting 3Health News:DaVita Abstracts Accepted into American Society of Nephrology Meeting 4Health News:Media Spotlight Shines on Dr. Siegal's Cookie Diet While Major Study Reveals Doubling of U.S. Type II Diabetes Cases During Past Ten Years 2Health News:Media Spotlight Shines on Dr. Siegal's Cookie Diet While Major Study Reveals Doubling of U.S. Type II Diabetes Cases During Past Ten Years 3Health News:Response Biomedical to Present at Rodman and Renshaw 10th Annual Healthcare Conference 2
Phaco-emulsification systems CV series...
The unprecedented power, flexibility and versatility of the Series 20000 Legacy have made it the world's leading phacoemulsifier....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....
Medicine Products: